Draft results accidentally published Thursday by the World Health Organization on its website showed that Gilead Sciences’ closely watched COVID-19 candidate remdesivir failed to show clinical improvement in severely infected patients in a Chinese Phase III trial.

According to the draft, remdesivir had not reduced the presence of SARS-CoV-2 in the bloodstream of 158 patients treated with the antiviral candidate in the 237-patient trial. 18 patients were taken off the drug due to side effects.

“Remdesivir use was not associated with a difference in time to clinical improvement,” or mortality after 28 days, or in time to SARS-CoV-2 PCR, the draft stated, according to several published reports.

Twenty-eight days after treatment, 13.9% of the patients in the remdesivir cohort died, compared to 12.8% of untreated control patients